RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immune Pharmaceuticals Stock

Immune Pharmaceuticals P/S 2024

Immune Pharmaceuticals P/S

0

Ticker

IMNPQ

ISIN

US45254C2008

WKN

A2DQB0

As of Oct 15, 2024, Immune Pharmaceuticals's P/S ratio stood at 0, a 0% change from the 0 P/S ratio recorded in the previous year.

The Immune Pharmaceuticals P/S history

Immune Pharmaceuticals Aktienanalyse

What does Immune Pharmaceuticals do?

Immune Pharmaceuticals Inc is a biopharmaceutical company specialized in the development and commercialization of novel therapies for the treatment of inflammatory diseases and cancer. The company, headquartered in Israel, was founded in 2010 and has branches in the USA and Europe. History: Immune Pharmaceuticals started as a subsidiary of EpiCept Corporation, a biopharmaceutical company focused on the development of pain medications. In October 2009, EpiCept and Immune Pharmaceuticals separated due to the growing interest in inflammatory body response and cancer therapy. Since the split, the company has made progress in the development of medications based on a proven active ingredient, AmiKet. Business model: Immune Pharmaceuticals aims for the successful development and commercialization of innovative products for the treatment of inflammatory diseases and cancer. The company focuses on the discovery and development of medications that influence the role of leukocytes and cytokines in the inflammatory response. The company relies on partnerships with other leading companies and government authorities in the development of therapies. Divisions: Immune Pharmaceuticals has two business divisions. The first division, Immuno-Dermatology, focuses on the development of medications for the treatment of inflammatory diseases such as psoriasis and eczema. The second division, Immuno-Oncology, aims to develop groundbreaking cancer therapies to improve the survival rate of cancer patients. Products: Unfortunately, most of the products developed by Immune Pharmaceuticals are still in the preclinical development phase and need to prove themselves in clinical trials to be approved by the FDA and brought to the market. One of the most well-known products is the medication Bertilimumab, which is in development for the treatment of inflammatory bowel diseases and progressive supranuclear palsy (PSP). Additionally, Immune is also working on the development of nanoparticle therapies that target cancer cells. Summary: Immune Pharmaceuticals is a biopharmaceutical company specialized in the development of therapies for the treatment of inflammatory diseases and cancer. The company has two business divisions, Immuno-Dermatology and Immuno-Oncology, and is currently developing a portfolio of medications to increase the survival rate of cancer patients and alleviate inflammatory diseases such as psoriasis and eczema. The company has undergone a promising phase of medication development, and it remains to be seen if it will be able to bring these medications to the market. Immune Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Immune Pharmaceuticals's P/S Ratio

Immune Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Immune Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Immune Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Immune Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Immune Pharmaceuticals stock

What is the price-to-earnings ratio of Immune Pharmaceuticals?

The price-earnings ratio of Immune Pharmaceuticals is currently 0.

How has the price-earnings ratio of Immune Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Immune Pharmaceuticals has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Immune Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Immune Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Immune Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Immune Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Immune Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Immune Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Immune Pharmaceuticals?

Some factors that influence the price-earnings ratio of Immune Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Immune Pharmaceuticals pay?

Over the past 12 months, Immune Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immune Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Immune Pharmaceuticals?

The current dividend yield of Immune Pharmaceuticals is .

When does Immune Pharmaceuticals pay dividends?

Immune Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immune Pharmaceuticals?

Immune Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Immune Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immune Pharmaceuticals located?

Immune Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immune Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immune Pharmaceuticals from 10/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.

When did Immune Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/15/2024.

What was the dividend of Immune Pharmaceuticals in the year 2023?

In the year 2023, Immune Pharmaceuticals distributed 0 USD as dividends.

In which currency does Immune Pharmaceuticals pay out the dividend?

The dividends of Immune Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immune Pharmaceuticals

Our stock analysis for Immune Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immune Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.